Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses
Alnylam Pharmaceuticals (ALNY) is drawing attention after advancing its Alzheimer’s disease pipeline by initiating a Phase 2 trial of mivelsiran in Down syndrome-associated Alzheimer’s and completing enrollment in a related cerebral amyloid angiopathy study.
See our latest analysis for Alnylam Pharmaceuticals.
Despite the Alzheimer’s updates, Alnylam Pharmaceuticals’ share price has come under pressure, with the stock down 10.47% over the past week and 33.16% on a year to date share price return. However, the 5 year total shareholder return of 46.63% points to longer term momentum that has previously rewarded patient holders.
If this kind of neuroscience pipeline progress interests you, it can be worth widening the lens to other potential opportunities in healthcare AI, starting with the 39 healthcare AI stocks
After a sharp recent pullback, Alnylam Pharmaceuticals now trades at a sizeable discount to both analyst targets and intrinsic value estimates. Is that pricing in genuine pipeline risk, or has caution swung too far, too fast?
Most Popular Narrative: 38.5% Undervalued
With Alnylam Pharmaceuticals last closing at $267.47 against a narrative fair value of $434.72, the current price reflects a sizable gap that the most followed thesis tries to explain.
The rapid and robust uptake of AMVUTTRA for ATTR-CM in its first full quarter post-approval, combined with near-universal first-line payer access and minimal patient out-of-pocket costs, indicates a much larger addressable market for Alnylam's RNAi therapies as diagnostics and disease awareness improve, supporting sustained double-digit revenue growth. International expansion for AMVUTTRA in major markets (Germany, Japan, Brazil, EU) is only just starting and is expected to contribute meaningful incremental revenue in the second half of the year and beyond, with global rollouts benefiting from favorable reimbursement dynamics for high-impact orphan drugs.
Curious what earnings path and margin profile could justify that higher fair value for Alnylam Pharmaceuticals? The narrative leans on brisk revenue growth, rising profitability and a rich future earnings multiple that many investors usually associate with faster growing sectors. The exact mix of those assumptions might surprise you.
Result: Fair Value of $434.72 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Alnylam Pharmaceuticals still faces two clear swing factors: execution on its TTR franchise and potential pricing or reimbursement pressure on key RNAi therapies.
Find out about the key risks to this Alnylam Pharmaceuticals narrative.
Another View on Alnylam Pharmaceuticals’ Valuation
While the narrative fair value of $434.72 frames Alnylam Pharmaceuticals as 38.5% undervalued, the current P/E of 66.4x tells a much tougher story. It is far above the US Biotechs industry at 17.1x, the peer average of 31.8x, and even its own fair ratio of 34.6x. This points to meaningful valuation risk if sentiment cools.
That kind of premium raises a simple question for you as an investor: are you being paid enough in potential upside to accept the risk that the market could drift back toward the fair ratio or closer to industry and peer levels over time?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling cautious or optimistic after looking at Alnylam Pharmaceuticals so far? Act while sentiment is in flux by reviewing the 4 key rewards
Looking for more investment ideas beyond Alnylam Pharmaceuticals?
If you like the kind of detail you have seen on Alnylam Pharmaceuticals, do not stop here. The next strong opportunity could already be on your radar.
- Target potential bargains early by checking companies that screen as attractively valued through the 47 high quality undervalued stocks.
- Strengthen your income toolkit by scanning for companies with strong yields and resilience using the 8 dividend fortresses.
- Reduce portfolio stress by focusing on companies that score well on financial resilience through the 84 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com